BiotechTube

ONO-9054 + Latanoprost

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Hypertension

Conditions

Ocular Hypertension, Open Angle-glaucoma

Trial Timeline

May 1, 2014 → —

NCT ID
NCT02083289

About ONO-9054 + Latanoprost

ONO-9054 + Latanoprost is a phase 2 stage product being developed by Ono Pharmaceutical for Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02083289. Target conditions include Ocular Hypertension, Open Angle-glaucoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02083289Phase 2Completed

Competing Products

20 competing products in Ocular Hypertension

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
47
Mirabegron + PlaceboAstellas PharmaPhase 1
33
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
33
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
77
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
23
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
77
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
dorzolamide hydrochloride (+) timolol maleateMerckApproved
85
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
33
SAD448NovartisPhase 1
33
MGV354 ophthalmic suspension + MGV354 placeboNovartisPhase 1/2
41

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77